Description:Terazosin EP Impurity O, with the CAS number 547730-06-3, is a chemical compound that is recognized as an impurity associated with the pharmaceutical agent terazosin, which is primarily used to treat hypertension and benign prostatic hyperplasia. As an impurity, it may arise during the synthesis or degradation of terazosin and is typically characterized by its molecular structure, which includes specific functional groups that can influence its chemical behavior. The compound may exhibit properties such as solubility in organic solvents, stability under certain conditions, and potential biological activity, although its specific pharmacological effects are less well-documented compared to the parent compound. Analytical techniques such as HPLC (High-Performance Liquid Chromatography) and mass spectrometry are often employed to identify and quantify impurities like Terazosin EP Impurity O in pharmaceutical formulations. Understanding the characteristics of such impurities is crucial for ensuring the safety and efficacy of drug products, as well as for compliance with regulatory standards in pharmaceutical manufacturing.
We use cookies to enhance your visit. We do not include advertising.
Please see our Cookies Policy for more details or adjust your preferences in "Settings".
This is the advanced settings system for our own and third-party cookies. Here you can modify parameters that will directly affect your browsing experience on this website. If you wish you may check the list of Cookie types.
Please note that disabling cookies can cause failures in the normal operation of the web.
![1,4-Bis[(tetrahydrofuran-2-yl)carbonyl]piperazine](https://static.cymitquimica.com/products/86/thumb/MM0843.16.jpg)
![1,4-Bis[(tetrahydro-2-furanyl)carbonyl]-piperazine](https://static.cymitquimica.com/products/TR/thumb/B585325.jpg)
![1,4-Bis[(tetrahydro-2-furanyl)carbonyl]-piperazine](https://static.cymitquimica.com/products/3D/thumb/IB63853.jpg)
